Key facts
- Cirius Therapeutics will present clinical data on CIR-0602K.
- CIR-0602K is a novel treatment for type 2 diabetes.
- The presentation will occur at the American Diabetes Association's 2026 Scientific Sessions.
- Cirius Therapeutics develops therapies for mitochondrial dysfunction and insulin resistance.
The American Diabetes Association (ADA) Scientific Sessions are a premier scientific meeting dedicated to diabetes research. Presentations at this forum often highlight new findings and potential treatments for diabetes, a chronic condition affecting millions worldwide. Cirius Therapeutics' announcement indicates they will share data on a new therapeutic approach targeting underlying mechanisms of type 2 diabetes.